Stay updated on ARGX-113 in Myasthenia Gravis: Efficacy Study Clinical Trial
Sign up to get notified when there's something new on the ARGX-113 in Myasthenia Gravis: Efficacy Study Clinical Trial page.

Latest updates to the ARGX-113 in Myasthenia Gravis: Efficacy Study Clinical Trial page
- CheckyesterdayChange DetectedThe page has removed a citation regarding the safety, efficacy, and tolerability of efgartigimod in patients with generalized myasthenia gravis, which was previously included.SummaryDifference0.3%
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant content removal, particularly regarding the details of a Phase 3 trial for ARGX-113 in patients with generalized Myasthenia Gravis, including inclusion and exclusion criteria, and the study director's name. A new version number has been added.SummaryDifference11%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to ARGX-113 in Myasthenia Gravis: Efficacy Study Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ARGX-113 in Myasthenia Gravis: Efficacy Study Clinical Trial page.